MILNE GEORGE M JR 5
5 · Amylyx Pharmaceuticals, Inc. · Filed Feb 14, 2023
Insider Transaction Report
Form 5
MILNE GEORGE M JR
Director
Transactions
- Conversion
Series C-2 Preferred Stock
2022-01-06−23,212→ 0 total→ Common Stock (23,212 underlying) - Conversion
Common Stock
2022-01-06+689,425→ 910,821 total - Gift
Common Stock
2022-12-29−13,800→ 897,021 total - Conversion
Series A Preferred Stock
2022-01-06−262,282→ 0 total→ Common Stock (262,282 underlying) - Conversion
Series B Preferred Stock
2022-01-06−384,449→ 0 total→ Common Stock (384,449 underlying) - Conversion
Series C-1 Preferred Stock
2022-01-06−19,482→ 0 total→ Common Stock (19,482 underlying)
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.